open access

Vol 26, No 4 (2022)
Original paper
Published online: 2022-11-28
Get Citation

Changes of apelin-13 concentration in patients with essential hypertension and extrasystole

Anastasiia Ivankova1, Nataliia Kuzminova1, Valerii Ivanov2, Sergiy Lozinsky3
DOI: 10.5603/AH.a2022.0018
·
Arterial Hypertension 2022;26(4):141-145.
Affiliations
  1. Department of Internal Medicine No. 1, National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  2. Department of Internal Medicine No. 3, National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  3. Department of Internal Medicine of Medical Faculty No. 2, National Pirogov Memorial Medical University, Vinnytsya, Ukraine

open access

Vol 26, No 4 (2022)
ORIGINAL PAPERS
Published online: 2022-11-28

Abstract

Background: Hypertension is one of the leading causes of disability and mortality among cardiovascular diseases, so today new metabolic markers of cardiovascular risk are being actively studied. One of them is apelin-13. The objective was to assess the concentration of apelin-13 in patients with essential hypertension and frequent extrasystoles.

Material and methods: One hundred fifty six patients with stage 2 essential hypertension were examined. One hundred twenty four of them had frequent symptomatic extrasystoles, 32 patients had no arrhythmias and were considered as the comparison group. Thirty apparently healthy normotensive persons were considered as the control group. All patients underwent a complete clinical and anthropometric examination, blood pressure measurement, automatic daily blood pressure monitoring, daily electrocardiogram monitoring, echocardiography and the assessment of serum apelin-13 concentration.

Results: It was found that the concentration of apelin-13 in patients with hypertension was significantly lower compared to the control group. Moreover, the average content of apelin-13 was significantly (p = 0.02) lower in patients with extrasystole than in those without arrhythmia. The lowest concentration of apelin-13 was noticed in patients with ventricular arrhythmias.

Conclusion: The results confirm the existing assumptions about the protective role of apelin-13 in preventing the progression of cardiovascular diseases due to counteracting the increase in blood pressure and life-threatening arrhythmias.

Abstract

Background: Hypertension is one of the leading causes of disability and mortality among cardiovascular diseases, so today new metabolic markers of cardiovascular risk are being actively studied. One of them is apelin-13. The objective was to assess the concentration of apelin-13 in patients with essential hypertension and frequent extrasystoles.

Material and methods: One hundred fifty six patients with stage 2 essential hypertension were examined. One hundred twenty four of them had frequent symptomatic extrasystoles, 32 patients had no arrhythmias and were considered as the comparison group. Thirty apparently healthy normotensive persons were considered as the control group. All patients underwent a complete clinical and anthropometric examination, blood pressure measurement, automatic daily blood pressure monitoring, daily electrocardiogram monitoring, echocardiography and the assessment of serum apelin-13 concentration.

Results: It was found that the concentration of apelin-13 in patients with hypertension was significantly lower compared to the control group. Moreover, the average content of apelin-13 was significantly (p = 0.02) lower in patients with extrasystole than in those without arrhythmia. The lowest concentration of apelin-13 was noticed in patients with ventricular arrhythmias.

Conclusion: The results confirm the existing assumptions about the protective role of apelin-13 in preventing the progression of cardiovascular diseases due to counteracting the increase in blood pressure and life-threatening arrhythmias.

Get Citation

Keywords

essential arterial hypertension; apelin-13; extrasystole; smoking; obesity

About this article
Title

Changes of apelin-13 concentration in patients with essential hypertension and extrasystole

Journal

Arterial Hypertension

Issue

Vol 26, No 4 (2022)

Article type

Original paper

Pages

141-145

Published online

2022-11-28

Page views

509

Article views/downloads

61

DOI

10.5603/AH.a2022.0018

Bibliographic record

Arterial Hypertension 2022;26(4):141-145.

Keywords

essential arterial hypertension
apelin-13
extrasystole
smoking
obesity

Authors

Anastasiia Ivankova
Nataliia Kuzminova
Valerii Ivanov
Sergiy Lozinsky

References (12)
  1. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75(6): 1334–1357.
  2. Tian Y, Chen R, Jiang Y, et al. The Protective Effects and Mechanisms of Apelin/APJ System on Ischemic Stroke: A Promising Therapeutic Target. Front Neurol. 2020; 11: 75.
  3. Koguchi W, Kobayashi N, Takeshima H, et al. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J. 2012; 76(1): 137–144.
  4. Tycinska AM, Lisowska A, Musial WJ, et al. Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta. 2012; 413(3-4): 406–410.
  5. Hu G, Wang Z, Zhang R, et al. The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review. Front Physiol. 2021; 12: 632886.
  6. Saravi SS, Beer J. Apelin-potential therapy for COVID-19? J Mol Cell Cardiol. 2020; 145: 84–87.
  7. Wang X, Tian X, Pei LL, et al. The Association Between Serum Apelin-13 and the Prognosis of Acute Ischemic Stroke. Transl Stroke Res. 2020; 11(4): 700–707.
  8. Falcone C, Buzzi MP, D'Angelo A, et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol. 2010; 23(3): 917–925.
  9. Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer. Front Physiol. 2018; 9: 557.
  10. El Wakeel MA, El-Kassas GM, Kamhawy AH, et al. Serum Apelin and Obesity-Related Complications in Egyptian Children. Open Access Maced J Med Sci. 2018; 6(8): 1354–1358.
  11. Kuzminova NV, Ivankova AV, Lozinsky SE, et al. State of kidney function and features of metabolic status changes in patients with different forms of extrasystols. World Med Biol. 2019; 15(69): 083.
  12. Hoogendijk MG, Géczy T, Yap SC, et al. Pathophysiological Mechanisms of Premature Ventricular Complexes. Front Physiol. 2020; 11: 406.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl